Every review,
one place.
A clean article index with active, working links. Each piece includes its evidence label, review date, grade, and medical-advice disclaimer.
Tirzepatide, after the hype.
The uncomfortable parts of the GLP-1 boom that rarely make it into glossy before-and-afters: tolerance, muscle retention, cost, access, and what happens when treatment stops.
Semaglutide vs. Tirzepatide: a 36-week head-to-head.
Mean BMI loss, lean-mass preservation, lipid panels and the side-effect curve nobody charts honestly.
Epitalon: the longevity peptide that won't quit the headlines.
Old research, modern protocols, and why telomere language can sound more settled than the evidence actually is.
Polynucleotide salmon DNA injectables, audited.
What early dermatology data and patient photos suggest: texture looks more plausible than lift, and the word “regenerative” needs a haircut.
The case for early HRT — and the studies that quietly buried the WHI.
Timing, symptom burden, bone density, risk stratification, and why menopause medicine still argues with a 2002 headline.
CJC-1295 / Ipamorelin: the growth-hormone stack, demystified.
Recovery claims, sleep anecdotes, glucose tradeoffs, and why the protocol matters more than the peptide-shop sales page.
Tretinoin at 0.025%, every other night, for ten years.
The boring skincare active that still beats most launches — if your barrier survives the onboarding period.